Clinical trials: Chemotherapy Toxicity
- Condition Chemotherapy Toxicity
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Neutropenic Complications, Breast Neoplasms
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®
The study will assess the efficacy of LA-EP2006 compared to Neulasta® with respect to the mean duration of severe neutropenia during treatment with myelosuppressive chemotherapy in breast cancer patients.
- Conditions
- Neutropenic Complications, Breast Neoplasms, Chemotherapy-induced Neutropenia, Chemotherapeutic Toxicity
- Trial name
- PROTECT-1 (NCT01735175)
- Testing
- LA-EP2006, Neulasta®
- Where
- 41 sites in Brazil, India and 4 more
- Volunteers
- 316 people
- Sponsor
- Sandoz
Pancreatic Cancer
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer
A prospective, open-label phase 2/3 trial in metastatic pancreatic cancer participants who have failed two lines of prior systemic therapy.
- Trial name
- NCT03512756
- Testing
- SM-88 used with MPS (methoxsalen, phenytoin, sirolimus), Capecitabine, Gemcitabine, and 5-FU
- Where
- 20 sites in United States
- Volunteers
- 130 people
- Sponsor
- Tyme, Inc
Colorectal Cancer Metastatic, Myelosuppression-Adult
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
This was a randomized, double-blind, placebo-controlled, global, multicenter, Phase 3 trial evaluating the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in…
- Conditions
- Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity
- Trial name
- PRESERVE1 (NCT04607668)
- Testing
- Trilaciclib
- Where
- 82 sites in United States, China and 6 more
- Volunteers
- 326 people
- Sponsor
- G1 Therapeutics, Inc.
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy
This study will evaluate the efficacy and safety of Tarceva in two groups of patients with non-small cell lung cancer who have not been pre-treated with chemotherapy.
- Trial name
- NCT02013206
- Testing
- erlotinib [Tarceva]
- Where
- 11 sites in France, Germany and 4 more
- Volunteers
- 52 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer, Skin Rash
Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with…
- Conditions
- Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities, Colon Cancer
- Trial name
- STEPP (NCT00332163)
- Testing
- Panitumumab, Irinotecan, FOLFIRI
- Volunteers
- 95 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva, compared with placebo, following platinum-based chemotherapy in patients with advanced, recurrent, or metastatic NSCLC who have not had disease…
- Trial name
- NCT00556712
- Testing
- erlotinib [Tarceva]
- Where
- 133 sites in Australia, Austria and 26 more
- Volunteers
- 889 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer (NSCLC)
Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
This is a double blind, multicentre, randomized, placebo-controlled study. The eligible patients will be randomized to receive gefitinib or placebo at 1:1 ratio.
- Trial name
- INFORM (NCT00770588)
- Testing
- Gefitinib
- Where
- 14 sites in China
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based…
- Trial name
- NCT01230710
- Testing
- Erlotinib
- Where
- 7 sites in India
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche